Phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in metastatic renal cell carcinoma | Dr James Larkin at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lenvatinib is an oral tyrosine kinase inhibitor of the VEGFR13, FGFR14, PDGFR?, RET, and KIT signaling networks.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews